2nd European Laser Innovations Forum
You are invited to Ellex in Nice, France, for the 2nd European Laser Innovations Forum. A panel of world-renowned faculty, including John Marshall, PhD, FRCPath, FMedSci, Prof. Paulo E. Stanga, MD, PhD and Isabelle Aknin, MD will share their collective experiences and latest updates of laser therapies in ophthalmology.
Date: Saturday, 6th April 2019
Time: 9.00 am – 4.30 pm
Venue: Hotel Le Negresco
37, Promenade des Anglais
06000 Nice, France
M. Francois Checinski
+33 482 91 04 60
Note: Welcome Cocktail Reception will be held in Le Negresco from 8:00pm on Friday, 5th April 2019.
Due to the limited number of places available, registration confirmation is required on or before 29 March 2019.
Early-bird rate: 70.00 EUR (22nd February 2019 deadline)
Full rate: 90.00 EUR
Hôtel WEST END Nice
31, Promenade des Anglais, 06000 Nice – France
To book your accommodation with special rates contact: email@example.com by 22nd February 2019.
WELCOME COCKTAIL RECEPTION
Welcome Cocktail Reception in Le Negresco from 8:00pm on Friday, 5th April 2019.
LFT - LASER FLOATER TREATMENT
Moderators: Prof. Paulo E. Stanga (U.K.), Dr. Isabelle Aknin (FR)
SLT - SELECTIVE LIGHT THERAPY
Moderators: Prof. John Marshall (U.K.), Dr. Isabelle Aknin (FR)
2RT® - RETINAL REJUVENATION THERAPY
Moderators: Prof. John Marshall (U.K.), Dr Isabelle Aknin (FR)
Please note that the full program will be in English.
PROACTIVE GLAUCOMA CARE
Ellex is at the vanguard of working with physicians to transform outcomes and quality of life for patients with glaucoma. Our leading edge SLT Selective Light Therapy and ABiC™ – our restorative solution for minimally invasive glaucoma surgery, performed with the iTrack™ surgical system – offer the ability to intervene earlier in the treatment of glaucoma, and to treat across the full spectrum of the disease, and thereby enable significant numbers of patients to minimize or obviate the need for medications to control their glaucoma.
Professor John Marshall is an Emeritus Professor of Ophthalmology at Kings College London, and Honorary Distinguished Professor University of Cardiff. His research over the past forty years has ranged over a number of ocular problems but has concentrated on the interrelationships between light and ageing, the environmental mechanisms underlying age-related, diabetic and inherited retinal disease, and the development of lasers for use in ophthalmic diagnosis and surgery. This work has resulted in over four hundred research papers and 41 book chapters and 7 books. He has held posts chairing the medical advisory boards of many international companies and was a director of Diomed for some years, this being the leading supplier of diode laser systems for surgery. He is a Fellow of several national ophthalmological societies, as well as being elected to the European Academy of Ophthalmology.
Prof. Paulo E. Stanga is a Consultant Ophthalmologist and Vitreoretinal Surgeon for the Manchester Royal Eye Hospital (MREH) and Professor of Ophthalmology and Retinal Regeneration for the University of Manchester. He previously held the positions of Lecturer in Ophthalmology for the University of Liverpool, Vitreoretinal Fellow at the Royal Liverpool University Hospital, Medical Retina Fellow at Moorfields Eye Hospital and Retina Research Fellow, New York Hospital, Cornell University Medical College, New York, USA.
Prof. Stanga is the Chairman of the MREH Research Steering Committee in support of the development and introduction into clinical care of medical devices, both diagnostic/imaging and therapeutic, as well as new surgical techniques/therapies.
Since 1993, Prof. Stanga has worked in the development and application of new outpatient and surgical therapies and technologies. His current research interests include vitreo-retinal imaging, pharmacological, surgical and laser treatment of Proliferative Diabetic Retinopathy and Macular Oedema, Laser-Tissue Interaction, evelopment of a novel Ultrasound-based Vitrector, Electronic Retinal Implants for Artificial Vision and Stem-Cell Therapy.
Prof. Stanga is Director of the Manchester Vision Regeneration (MVR) Lab at MREH/NIHR/Wellcome Trust Manchester CRF and its Retinal Clinical-Research Fellowship Program. MVR Lab is arguably one of the best-equipped facilities in the world for retinal diagnostic imaging and laser treatment. Further, he directs an independent Clinical Research Fellowship Program at the Manchester Royal Eye Hospital and MVR Lab. The MVR Lab research team focuses on developing research and treatment strategies in Medical Retina and vitreoretinal conditions using the most advanced diagnostic and treatment devices.
Ophthalmological practice in Golfe-Juan, specializing in retinal pathologies and pathologies of ocular aging.
Retinal exploration Center at the Private Hospital Oxford in Cannes.
Aesthetic consultations at the Private Hospital Oxford in Cannes.
Member of SFO, American Diabetes Association, ARVO, American Academy of Ophthalmology, International Ocular Inflammation Society and Usher Syndrome Coalition.
Board of the French Retinal Society.
Former lecturer at the Faculty of Pharmacy, University of Dijon.
2009 Prize of the French Retinal Society.
President of ARMD: Association de la Rétine MeDiterranéenne.
SLT FROM ELLEX
Ellex’s proprietary SLT technology delivers superior energy control, a sharp-edged aiming beam and the industry’s fastest firing rate of three shots per second. It's a capability that's being used every day by thousands of physicians around the world to visualize the trabecular meshwork in greater detail, and to perform procedures faster and with improved accuracy, delivering better patient outcomes - reliably, accurately and safely.
FLOATER MANAGEMENT FROM ELLEX
Ellex was the first company to pioneer a laser designed specifically for the treatment of floaters. Our Reflex Technology™ platform features True Coaxial Illumination™ (TCI), on and off-axis modes, a precise aiming beam and a superior energy beam profile. It’s an approach that maximizes focusing accuracy and provides a safe and highly effective tool for the treatment of vitreous opacities.
REFLEX TECHNOLOGY FROM ELLEX
With Ellex’s proprietary Reflex Technology™ visualizing floaters and opacities, and assessing their position relative to the lens or retina, has never been easier.
“Featuring coaxial (on) and off-axis illumination, Reflex Technology allows for clear visualization of the internal eye from the cornea all the way to the retina, and as such, provides much-needed spatial context for procedures like laser floater treatment.”
2RT RETINAL REJUVENATION FROM ELLEX
Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT®offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow the degeneration process.
“The major difference between 2RT nanopulse laser therapy and conventional lasers is the difference in the responses in the patient. With a conventional laser, you will always get some collateral damage to the light sensitive cells. With 2RT being this disruptive mechanism, we have no collateral damage and therefore we get the therapeutic effect with none of the collateral effects of damage to the light sensitive cells.”
Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.
2RT® has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.
2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).